Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Type d'étude:

Retrospective Studies

Numéro de l'étude:

8410033

Type de traitement:

Maladies:

Auto immune disorders

Titre court:

CMV EBV reactivation

Objectif principal:

To identify the cumulative incidence, risk factors and outcome of CMV/EBV viraemia (ie, virus detection without clinical symptoms), CMV/EBV disease (ie, detection of viraemia and clinically relevant end organ disease) and CMV/EBV clinically significant infection (CMV/EBV viraemia leading to pre-emptive treatment) in patients who received autologous HSCT for an autoimmune disease (AD) at 100 days and 1 year following auto-HSCT. To assess centre practice in screening and treatment of CMV and EBV in the context of auto-HSCT for AD.

Principaux critères d'inclusion:

All patients registered in the EBMT database receiving a first autologous HSCT for AD between 2009 and 2019

Pays:

Investigateur principal:

Tobias Alexander

Coordinateur EBMT de l'étude:

Manuela Badoglio

E-mail du coordinateur de l'étude:

manuela.badoglio@upmc.fr